Average cost of drugs for extensively drug-resistant tuberculosis in Afghanistan
Afghanistan: Average cost of drugs for extensively drug-resistant tuberculosis was 2,000 constant 2022 US$ in 2024. ▼ Falling
Average cost of drugs for extensively drug-resistant tuberculosis in Afghanistan, 2017–2024
Source: WHO (2025) – with minor processing by Our World in Data. Measured in constant 2022 US$.
Analysis
In 2024, average cost of drugs for extensively drug-resistant tuberculosis in Afghanistan stood at 2,000 constant 2022 US$.
The figure is down 35.5% over ten years.
That places Afghanistan 24th out of 56 countries with data for 2024, putting it in the middle of the range.
Average cost of drugs for extensively drug-resistant tuberculosis in Afghanistan, year by year
| Year | constant 2022 US$ | Change |
|---|---|---|
| 2017 | 3,100 constant 2022 US$ | — |
| 2018 | 2,000 constant 2022 US$ | -35.5% |
| 2019 | 2,700 constant 2022 US$ | +35.0% |
| 2020 | 2,500 constant 2022 US$ | -7.4% |
| 2021 | 1,000 constant 2022 US$ | -60.0% |
| 2022 | 2,000 constant 2022 US$ | +100.0% |
| 2023 | 2,000 constant 2022 US$ | +0.0% |
| 2024 | 2,000 constant 2022 US$ | +0.0% |
Afghanistan compared with similar countries
- Afghanistan's 2,000 constant 2022 US$ is above the median for low income countries, which is 1,709 constant 2022 US$, 1.2× the median. (9 countries reporting)
- Afghanistan's 2,000 constant 2022 US$ is above the median for Middle East, North Africa, Afghanistan & Pakistan, which is 2,000 constant 2022 US$, 1.0× the median. (7 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 2,600 constant 2022 US$ | 2,000 constant 2022 US$ | 3,100 constant 2022 US$ | 3 |
| 2020s | 1,900 constant 2022 US$ | 1,000 constant 2022 US$ | 2,500 constant 2022 US$ | 5 |
Countries ranked near Afghanistan
More reference data data for Afghanistan
- Emission Totals - Indirect emissions (N2O) - Manure applied to Soils 0.8991 (2050)
- Emission Totals - Indirect emissions (N2O) - Manure left on Pasture 4.89 (2050)
- Emission Totals - Indirect emissions (N2O) - IPCC Agriculture 6.63 (2050)
- Emission Totals - Indirect emissions (N2O) - Crop Residues 0.4362 (2050)
- Emission Totals - Indirect emissions (N2O) - Agricultural Soils 6.63 (2050)
- Emission Totals - Emissions (N2O) - Manure applied to Soils 3.01 (2050)
- Emission Totals - Emissions (N2O) - Manure Management 0.847 (2050)
- Emission Totals - Emissions (N2O) - Manure left on Pasture 18.65 (2050)
- Emission Totals - Emissions (N2O) - IPCC Agriculture 26.62 (2050)
- Emission Totals - Emissions (N2O) - Crop Residues 2.38 (2050)
Frequently asked questions
- What is average cost of drugs for extensively drug-resistant tuberculosis in Afghanistan?
- Average cost of drugs for extensively drug-resistant tuberculosis in Afghanistan was 2,000 constant 2022 US$ in 2024, according to WHO (2025) – with minor processing by Our World in Data.
- What is the highest average cost of drugs for extensively drug-resistant tuberculosis recorded in Afghanistan?
- The highest recorded value was 3,100 constant 2022 US$ in 2017.
- What is the lowest average cost of drugs for extensively drug-resistant tuberculosis recorded in Afghanistan?
- The lowest recorded value was 1,000 constant 2022 US$ in 2021.
- How does Afghanistan rank for average cost of drugs for extensively drug-resistant tuberculosis?
- Afghanistan ranks 24th out of 56 countries with data for 2024.
- Is average cost of drugs for extensively drug-resistant tuberculosis rising or falling in Afghanistan?
- Over the last ten years it is down 35.5%. The long-run trend across the full record is falling.
- Where does this Afghanistan data come from?
- The figures come from WHO (2025) – with minor processing by Our World in Data, published as part of Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 8 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.